Stephens Inc. AR Has $525,000 Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Stephens Inc. AR boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 50.8% in the third quarter, according to its most recent filing with the SEC. The firm owned 6,445 shares of the medical equipment provider’s stock after acquiring an additional 2,172 shares during the period. Stephens Inc. AR’s holdings in Hologic were worth $525,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of HOLX. Prentiss Smith & Co. Inc. boosted its position in shares of Hologic by 0.3% during the third quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock worth $3,967,000 after purchasing an additional 130 shares in the last quarter. Massmutual Trust Co. FSB ADV boosted its position in shares of Hologic by 20.3% during the second quarter. Massmutual Trust Co. FSB ADV now owns 831 shares of the medical equipment provider’s stock worth $62,000 after purchasing an additional 140 shares in the last quarter. Wedmont Private Capital boosted its position in shares of Hologic by 3.7% during the third quarter. Wedmont Private Capital now owns 4,519 shares of the medical equipment provider’s stock worth $361,000 after purchasing an additional 162 shares in the last quarter. Sequoia Financial Advisors LLC boosted its position in shares of Hologic by 2.3% during the second quarter. Sequoia Financial Advisors LLC now owns 7,215 shares of the medical equipment provider’s stock worth $536,000 after purchasing an additional 165 shares in the last quarter. Finally, Curbstone Financial Management Corp boosted its position in shares of Hologic by 0.9% during the second quarter. Curbstone Financial Management Corp now owns 23,126 shares of the medical equipment provider’s stock worth $1,717,000 after purchasing an additional 200 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Evercore ISI lifted their price target on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Royal Bank of Canada lifted their price target on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research report on Tuesday. StockNews.com cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday. UBS Group boosted their price objective on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research report on Tuesday. Finally, Citigroup cut shares of Hologic from a “buy” rating to a “neutral” rating and cut their price objective for the company from $95.00 to $85.00 in a research report on Tuesday, October 1st. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $89.25.

Hologic Stock Up 2.1 %

Shares of HOLX stock opened at $80.49 on Thursday. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. Hologic, Inc. has a 1 year low of $66.93 and a 1 year high of $84.67. The firm’s fifty day moving average price is $81.05 and its two-hundred day moving average price is $78.11. The firm has a market capitalization of $18.70 billion, a P/E ratio of 24.17, a PEG ratio of 3.03 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 20.11%. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same period in the previous year, the business earned $0.89 EPS. The company’s revenue was up 4.5% compared to the same quarter last year. On average, equities analysts predict that Hologic, Inc. will post 4.36 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.